According to Stock Talk (@stocktalkweekly), Citizens JMP has reiterated its 'Outperform' rating on CRISPR Therapeutics (CRSP) and set an $86 price target, following a significant gene-editing M&A deal that marks a major milestone for the technology. The report highlights recent collaborations between Eli Lilly (LLY) and Verve Therapeutics (VERV), noting growing institutional confidence in gene-editing's commercial potential. For crypto traders, the surge in biotech M&A and institutional adoption of advanced gene-editing technologies could boost market sentiment for blockchain projects focusing on healthcare or biotech tokenization, creating new cross-sector momentum. (Source: Stock Talk on Twitter, June 18, 2025)